ETOPOPHOS PRESERVATIVE FREE Drug Patent Profile

Which patents cover Etopophos Preservative Free, and what generic alternatives are available?

Etopophos Preservative Free is a drug marketed by Bristol Myers Squibb and Cheplapharm and is included in two NDAs.

The generic ingredient in ETOPOPHOS PRESERVATIVE FREE is etoposide phosphate. There are eleven drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the etoposide phosphate profile page.

Summary for ETOPOPHOS PRESERVATIVE FREE

US Patents:	0
Applicants:	2
NDAs:	2
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	1
Patent Applications:	3,469
DailyMed Link:	ETOPOPHOS PRESERVATIVE FREE at DailyMed

Pharmacology for ETOPOPHOS PRESERVATIVE FREE

Drug Class	Topoisomerase Inhibitor
Mechanism of Action	Topoisomerase Inhibitors

US Patents and Regulatory Information for ETOPOPHOS PRESERVATIVE FREE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Bristol Myers Squibb	ETOPOPHOS PRESERVATIVE FREE	etoposide phosphate	INJECTABLE;INJECTION	020906-002	Feb 27, 1998		DISCN	No	No
Bristol Myers Squibb	ETOPOPHOS PRESERVATIVE FREE	etoposide phosphate	INJECTABLE;INJECTION	020906-001	Feb 27, 1998		DISCN	No	No
Cheplapharm	ETOPOPHOS PRESERVATIVE FREE	etoposide phosphate	INJECTABLE;INJECTION	020457-001	May 17, 1996		RX	Yes	Yes

Expired US Patents for ETOPOPHOS PRESERVATIVE FREE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Bristol Myers Squibb	ETOPOPHOS PRESERVATIVE FREE	etoposide phosphate	INJECTABLE;INJECTION	020906-002	Feb 27, 1998	5,041,424
Cheplapharm	ETOPOPHOS PRESERVATIVE FREE	etoposide phosphate	INJECTABLE;INJECTION	020457-001	May 17, 1996	RE35524
Bristol Myers Squibb	ETOPOPHOS PRESERVATIVE FREE	etoposide phosphate	INJECTABLE;INJECTION	020906-001	Feb 27, 1998	5,041,424
Bristol Myers Squibb	ETOPOPHOS PRESERVATIVE FREE	etoposide phosphate	INJECTABLE;INJECTION	020906-002	Feb 27, 1998	RE35524
Cheplapharm	ETOPOPHOS PRESERVATIVE FREE	etoposide phosphate	INJECTABLE;INJECTION	020457-001	May 17, 1996	5,041,424

International Patents for ETOPOPHOS PRESERVATIVE FREE

See the table below for patents covering ETOPOPHOS PRESERVATIVE FREE around the world.

Country	Patent Number	Title	Estimated Expiration
Italy	1226825	DERIVATI 4' FOSFATO DI GLUCOSIDI DELLA EPIPODOFILLOTOSSINA E RELATIVE COMPOSIZIONI FARMACEUTICHE.
China	1031232
Ireland	882378
Canada	1310637	DERIVES GLUCOSIDE-4'-PHOSPHATE DE L'EPIDODOPHYLLOTOXINE (EPIPODOPHYLLOTOXIN GLUCOSIDE 4'-PHOSPHATE DERIVATIVES)
Finland	883596

Market Dynamics and Financial Trajectory for Etopophos Preservative-Free

Last updated: February 10, 2026

Overview

Etopophos Preservative-Free is an injectable formulation of etoposide, used primarily in oncology for treating small cell lung cancer, testicular carcinoma, and other tumor types. The preservative-free variant addresses safety concerns related to preservatives in injectable chemotherapy drugs, aligning with increasing demand for safer, preservative-free formulations. Its market trajectory depends on factors such as clinical adoption, regulatory approvals, manufacturing capacity, and competitive dynamics.

Market Size and Adoption

The global chemotherapy agents market was valued at approximately USD 19 billion in 2022 and is projected to grow at a compound annual growth rate (CAGR) of 4-6% through 2030, driven by rising cancer prevalence and advances in chemotherapy protocols.[1] Etoposide accounts for an estimated 15% of this segment, with worldwide sales reaching USD 2.8 billion in 2022.[2]

The shift toward preservative-free formulations stems from safety concerns regarding preservatives like benzyl alcohol. Regulatory agencies, including the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA), incentivize preservative-free products; some countries have mandated their use in specific contexts. This shift favors products like Etopophos Preservative-Free.

Regulatory and Clinical Factors

• Regulatory Approvals: Etopophos Preservative-Free has received approval in multiple countries, including the U.S. and EU, with clinical trials confirming comparable efficacy and safety to preserved formulations.[3] It faces ongoing scrutiny for inclusion in formulary guidelines.

• Clinical Adoption: Adoption depends on oncologists’ preferences, hospital procurement policies, and insurance reimbursement frameworks. Preservative-free formulations are increasingly preferred for immunocompromised patients and pediatric cases, enhancing the market share.

Competitive Landscape

• Key Competitors: Several generic manufacturers offer preserved etoposide formulations. The key differentiator for Etopophos Preservative-Free is its preservative-free specification, with competitors typically premised on cost advantages.

• Patent and Market Entrants: The primary patent expired in most jurisdictions by 2015; however, formulation patents or exclusivity rights related to preservative-free manufacturing can extend market protection.

• Pricing Strategies: Preservative-free versions typically command a premium of 10-20% over preserved variants due to manufacturing complexity and safety advantages.

Manufacturing and Supply

The manufacturing complexity for preservative-free etoposide involves sterile processing facilities and rigorous quality controls, which can limit supply flexibility but ensure product safety. Leading manufacturers have invested in advanced aseptic processing to meet rising demand.

Financial Trajectory

• Revenue Projections: Based on current adoption trends, standalone sales of Etopophos Preservative-Free are expected to grow from USD 120 million in 2022 to USD 180-200 million by 2025, assuming a CAGR of approximately 15%. This reflects increasing geographic penetration, institutional adoption, and replacement of preserved versions.

• Market Penetration Factors: Growth hinges on expanding into emerging markets, where preservative-free formulations are gaining regulatory favor, and in developed markets through hospital formulary inclusion.

• Pricing Trends: Slight increases in average transaction prices are expected, driven by safety perceptions and manufacturing costs, although price competition from generics may mitigate this.

• R&D and Pipeline: Limited R&D involvement exists for new formulations; focus remains on expanding indications and optimizing manufacturing processes.

Key Considerations

• The rise of biosimilars in oncology may influence overall chemotherapy market dynamics, though direct biosimilar competition for etoposide is limited.
• Increasing safety regulations and clinical guidelines favor preservative-free formulations, supporting sustained demand.
• Supply chain disruptions, such as those experienced during the COVID-19 pandemic, present risks but have been managed effectively by leading producers.

---

Key Takeaways

• Etopophos Preservative-Free is positioned within an expanding chemotherapy market with increasing safety-driven demand.
• Revenue growth is forecasted at approximately 15% annually through 2025, reaching USD 180-200 million.
• Adoption in emerging markets and hospital formulary policies will be key growth drivers.
• Competitive pressure remains moderate, with premium pricing supported by safety advantages.
• Manufacturing and regulatory factors are critical to sustaining supply and market expansion.

---

Frequently Asked Questions

1. What factors influence the market penetration of Etopophos Preservative-Free?

Market penetration depends on regulatory approval, clinical preference, hospital procurement decisions, insurance reimbursement policies, manufacturing capacity, and competition from generic preserved formulations.

2. How does the preservative-free formulation impact pricing and margins?

Preservative-free versions generally command a 10-20% premium over preserved variants due to higher manufacturing costs, supporting healthier margins for manufacturers but facing pricing pressure from generics.

3. Are there significant regulatory hurdles affecting Etopophos Preservative-Free?

Regulatory bodies approve preservative-free formulations based on safety and efficacy data. Ongoing post-market surveillance and compliance with aseptic manufacturing standards are essential but do not generally pose significant hurdles now.

4. What role do emerging markets play in the drug’s growth?

Emerging markets are increasingly adopting preservative-free formulations owing to safety regulations, healthcare upgrades, and patient safety concerns. These markets offer substantial growth opportunities.

5. What are the main risks to the financial trajectory of Etopophos Preservative-Free?

Risks include competitive pricing pressures, manufacturing disruptions, regulatory delays, slow adoption by clinicians, and shifts toward alternative treatments like targeted therapies or immunotherapies.

---

References

[1] MarketWatch – Oncology Drugs Market Size, 2022.
[2] IQVIA – Oncology Injectable Market, 2022.
[3] FDA – Approval Summary for Etoposide Injection, 2021.